# Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

> **NCT02029001** · PHASE2 · RECRUITING · sponsor: **Centre Leon Berard** · enrollment: 900 (estimated)

## Conditions studied

- Malignant Solid Neoplasms

## Interventions

- **DRUG:** Nilotinib (400 mg BID)
- **DRUG:** Everolimus (10 mg QD)
- **DRUG:** Sorafenib (400 mg BID)
- **DRUG:** Lapatinib (1500 mg QD)
- **DRUG:** Pazopanib (800 mg QD)
- **DRUG:** Olaparib (300 mg BID)
- **COMBINATION_PRODUCT:** Durvalumab + Tremelimumab

## Key facts

- **NCT ID:** NCT02029001
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2014-03
- **Primary completion:** 2026-01
- **Final completion:** 2027-10
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2025-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02029001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02029001, "Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT02029001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*